Delivery Order SPE2DB25D9348-SPE2DB25FNMXM
- Not listed
- The Defense Logistics Agency awarded a delivery order valued at $9,114.54 to DMS Pharmaceutical Group Inc. for Perjeta 420 mg/14 ml vials on August 14, 2025, with an ultimate completion date of September 5, 2025. This firm fixed-price delivery order represents a pharmaceutical supply requirement with no set-aside designation. DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois, is the prime contractor on this award. The delivery...
- The Defense Logistics Agency awarded a delivery order valued at $91,145.20 to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois, for the supply of Perjeta 420 mg/14 ml vials. This firm fixed-price delivery order, issued on August 12, 2025, with an ultimate completion date of September 3, 2025, represents a targeted pharmaceutical procurement to support Department of Defense healthcare operations. The award carries no set-aside...
- The Defense Logistics Agency (DLA) issued a delivery order valued at $36,458.16 to DMS Pharmaceutical Group Inc. on September 17, 2025, for the supply of Perjeta (pertuzumab) 420 mg/14 mL vials. This firm fixed-price delivery order is expected to be completed by October 8, 2025, with fulfillment to occur at the contractor's location in Park Ridge, Illinois. The award was made without set-aside designation, and DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler,...
- The U.S. Defense Logistics Agency (DLA) awarded a firm fixed-price delivery order contract, valued at $8,509.92, to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois. The contract is for the delivery of the oncology drug Perjeta (pertuzumab) 420 mg/14 mL vial, with an ultimate completion date of October 10, 2024. This delivery order is part of a larger indefinite delivery contract (IDC) between DMS Pharmaceutical Group and the...
- The Defense Logistics Agency awarded a $31,900.82 firm fixed-price delivery order to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois, for 420 mg/14 mL vials of Perjeta, an oncology treatment medication. The award was issued on September 8, 2025, with an ultimate completion date of September 29, 2025, and carries no set-aside designation. This delivery order is issued under DMS Pharmaceutical Group's existing single-award...
- The Defense Logistics Agency (DLA) awarded a delivery order valued at $18,229.08 to DMS Pharmaceutical Group Inc. on August 19, 2025, for the supply of Perjeta 420 mg/14 mL vials. This firm fixed-price delivery order, with an ultimate completion date of September 10, 2025, will be performed at the vendor's location in Park Ridge, Illinois. The award carries no set-aside designation, allowing DMS Pharmaceutical Group to compete on its merits as a woman-owned small business pharmaceutical...
- The Defense Logistics Agency awarded a delivery order valued at $136,717.80 to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois, for the supply of Perjeta 420 mg/14 ml vials. The contract is a firm fixed-price delivery order with an ultimate completion date of September 29, 2025, and was awarded on September 8, 2025. This award was issued under DMS Pharmaceutical Group's existing single-award Indefinite Delivery Contract with the...
- The Defense Logistics Agency (DLA), operating under the Medical Supply Chain, awarded a delivery order valued at $91,145.20 to DMS Pharmaceutical Group Inc. on September 16, 2025, for the supply of Perjeta 420 mg/14 mL vials. This firm fixed-price delivery order is scheduled for completion by October 7, 2025, with performance taking place at the contractor's location in Park Ridge, Illinois. The award was made without a set-aside designation, allowing DMS Pharmaceutical Group to compete directly...
- The Defense Logistics Agency awarded a delivery order to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois, for the supply of Perjeta 420 mg/14 ml vials. The contract, awarded on September 15, 2025, carries a ceiling value of $27,343.62 and utilizes firm fixed-price pricing with an ultimate completion date of October 6, 2025. This delivery order was issued without a set-aside designation, enabling DMS Pharmaceutical Group to...
- This is a firm fixed-price delivery order contract awarded by the Defense Logistics Agency (DLA) to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois. The contract, valued at $17,019.84, is for the provision of Perjeta 420 mg/14 ml vials to support the recurring medical supply needs of military health facilities. DMS Pharmaceutical Group holds a significant indefinite delivery contract (IDC) with the DLA, valued at up to...
- SPE2DB25D9348Indefinite Delivery Contract
- SPE2DB25D9348-SPE2DB25FNMXMDelivery Order
The Defense Logistics Agency awarded a firm fixed-price delivery order valued at $18,229.08 to DMS Pharmaceutical Group Inc. for the supply of Perjeta (pertuzumab) 420 mg/14 mL vials. DMS Pharmaceutical Group, a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois, will perform this delivery order at its Park Ridge facility with an ultimate completion date of October 10, 2025. The award was issued on September 19, 2025, without a set-aside designation, allowing the company to compete directly in the federal pharmaceutical procurement market. This delivery order is issued under DMS Pharmaceutical Group's larger Indefinite Delivery Contract with the Defense Logistics Agency valued at $499,999,999 and extending through November 2026. The SPE2DB program vehicle enables DLA to procure a comprehensive range of pharmaceutical products, including branded and generic prescription drugs, biologics, and medical consumables to support the medical supply needs of Department of Defense healthcare facilities worldwide. Perjeta is a HER2-targeting monoclonal antibody used in cancer treatment, and this order reflects DMS Pharmaceutical Group's continued role as a critical supplier within the federal pharmaceutical supply chain serving military health systems.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $18.2k | 9/19/25 |